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Summary
 
The B cell–specific transmembrane protein RP-105 belongs to the family of 
 
Drosophila
 
 
 
toll
 
-like
proteins which are likely to trigger innate immune responses in mice and man. Here we dem-
onstrate that the Src-family protein tyrosine kinase Lyn, protein kinase C 
 
b
 
 I/II (PKC
 
b
 
I/II),
and Erk2-specific mitogen-activated protein (MAP) kinase kinase (MEK) are essential and
probably functionally connected elements of the RP-105–mediated signaling cascade in B cells.
We also find that negative regulation of RP-105–mediated activation of MAP kinases by mem-
brane immunoglobulin may account for the phenomenon of antigen receptor–mediated arrest
of RP-105–mediated B cell proliferation.
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A
 
ctivation of B cells during adaptive immune responses
requires coordinated signaling through the surface ex-
pressed antigen receptor and coreceptors such as CD19,
CD21, or CD22 (1). The combined antigen receptor- and
coreceptor-derived signals define the degree of B cell acti-
vation and the strength of humoral immune responses (2).
In contrast to adaptive immune responses, innate immune
responses are antigen receptor-independent and induced by
invariant molecular structures in pathogens (pathogen-asso-
ciated molecular pattern, PAMPs)
 
1
 
 via pattern-recognition
receptors (PRRs; reference 3). The common feature of B
cell-activating PAMPs such as bacteria cell wall lipopolysac-
charide (4), viral hemagglutinins (5, 6), or CpG-rich bacte-
rial DNA (7) lies in their ability to induce polyclonal B cell
activation as defined by strong proliferative responses asso-
ciated with upregulation of the surface expressed MHC
class II and costimulatory receptor molecules CD80 (B7.1)
and CD86 (B7.2) (8).
Responses of this type were found recently to be medi-
ated by a human homologue of the 
 
Drosophila
 
 
 
toll
 
 protein
(9). The expression of a constitutively active form of hu-
man 
 
toll
 
 in a monocytic cell line leads to induction of ex-
pression of inflammatory cytokines such as IL-1, IL-8, IL-6,
IFN-
 
g
 
, as well as to the expression of the costimulatory
molecule CD80 (9). Human 
 
toll 
 
belongs to the family of
leucine-rich PRRs which also comprises the LPS receptor
CD14 (10) and the 
 
toll
 
-like protein RP-105 (11). RP-105
is a 105-kD transmembrane protein expressed on the sur-
face of mature B cells in mice (12) and B lymphocytes and
dendritic cells in humans (13, 14). As in 
 
toll
 
 protein, the ex-
tracellular domain of RP-105 is characterized by the pres-
ence of multiple tandemly repeated leucine-rich motifs
separated from the single transmembrane domain by a car-
boxy-flanking region (11). The similarity between 
 
toll
 
 and
RP-105 is further strengthened by the presence of con-
served cysteine residues in the carboxy-flanking region of
 
toll
 
 and RP-105 (11). These cysteine residues are essential
for the regulation of signal transduction through 
 
toll 
 
(9)
and, possibly, RP-105.
Antibody-mediated cross-linking of RP-105 in vitro in-
duces a strong proliferative response in B cells that can be
inhibited by surface IgM (sIgM) cross-linking (15). Thus,
the simultaneous treatment of B cells with anti-RP-105
and anti-IgM or incubation of anti-RP-105–induced B cell
blasts with anti-IgM leads to cell growth arrest and apop-
 
1
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g
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b
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nase C 
 
b
 
 I/II; PRR, pattern recognition receptor; PTK, protein tyrosine
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totic death (15). The described signaling properties of RP-
105 suggest a possible role of this protein in regulation of B
cell activation during immune responses and invite ques-
tions about the mechanisms of RP-105–mediated signal
transduction. Using a combination of biochemical and ge-
netic approaches we analyzed the mechanism of RP-105–
mediated signaling. Our data demonstrate that the Src-family
protein tyrosine kinase Lyn, protein kinase C 
 
b
 
 I/II
(PKC
 
b
 
I/II) and Erk2-specific mitogen-activated protein
(MAP) kinase kinase MEK are essential and probably func-
tionally connected elements of the RP-105–mediated signal-
ing cascade. We also find that negative regulation of anti-
RP-105–induced activation of MAP kinases by membrane
immunoglobulin may account for the arrest of RP-105–
induced proliferation mediated by the antigen receptor.
 
Materials and Methods
 
Mice.
 
The 
 
lyn
 
-/-
 
, 
 
fyn
 
-/-
 
, and 
 
PKC
 
b
 
I/II
 
-/-
 
 mice were described
previously (16-18). 
 
Lyn
 
-/-
 
 mice that had developed splenomegaly
were not used.
 
 
 
The 
 
Blk
 
-/-
 
 mice were generated by using ES cells
in which exon 8, encoding the tyrosine kinase domain of Blk was
replaced by 
 
neo
 
r
 
 gene (Texido, G., manuscript in preparation).
The B cells expressing the dominant negative mutant of MEK
(dnMEK) were derived in vivo from chimeric RAG-2–deficient
mice, in which the lymphoid system was reconstituted with the
ES cells carrying multiple copies of the dnMEK transgene under
the control of B cell–specific regulatory elements (Carsetti, R., A.
Tarakhovsky, manuscript in preparation).
 
Cells and Antibodies.
 
Unless otherwise indicated tissue culture
media used was RPMI 1640 supplemented with 5% FCS, 2 mM
pyruvate, 2 mM glutamine, and 50 
 
m
 
M 
 
b
 
-mercaptoethanol.
Splenic B lymphocytes were purified as described (16, 18). Goat
or rabbit anti–mouse IgM (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) was used for the induction of sIgM-medi-
ated protein tyrosine phosphorylation and Ca
 
2
 
1
 
 mobilization in B
cells. AffiPure goat anti–mouse IgM (2.5 
 
m
 
g/ml; Dianova, Ham-
burg, Germany), IL-4 (25 U/ml; Genzyme Corp., Boston, MA)
and monoclonal anti-RP-105 antibody (12) were used for the ac-
tivation of B cells in vitro. Anti-Lyn and anti-Syk polyclonal anti-
sera were generated and used as described (19, 20). Rabbit anti-
Shc was a gift from Dr. Mary Crowley (Scripps Institute, La Jolla,
CA).
 
 
 
Anti-phosphotyrosine mAb-4G10 was from Upstate Bio-
technology Inc. (Lake Placid, NY). Polyclonal anti-Vav, anti-
Erk2, anti-JNK1/anti-JNK-2, and anti-p38 antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Cul-
ture supernatant of anti-Fc
 
g
 
RII-III (mAb2.4G2) was obtained
from cells from American Type Culture Collection (ATCC,
Rockville, MD).
 
Analysis of B Cell Proliferation and Upregulation of Activation
Markers.
 
Purified splenic B cells (5
 
 3 
 
10
 
6
 
/ml) were cultured for
24 h in 24-well flat-bottom plates in media supplemented with
10% FCS in the absence or presence of anti-RP-105. After incu-
bation, cells were stained with phycoerythrin-conjugated anti-
bodies to B220/CD45R (RA3-6B2), fluorescein-conjugated an-
tibodies to B7.2 (CD86; PharMingen, San Diego, CA), or MHC
class II (M5/114) and analyzed by two-color flow cytometry on a
FACScan
 
Ò
 
 (Becton Dickinson & Co., Sparks, MD). For dose-
dependent proliferative response, purified splenic B cells were
cultured at 2
 
 3 
 
10
 
5
 
/well or at 4
 
 3 
 
10
 
5
 
/well in 96-well flat-bot-
tom plates for 36 h followed by the addition of [
 
3
 
H]thymidine
(1 
 
m
 
Ci/well) for the next 8 h. The cells were harvested on filters
and the incorporation of [
 
3
 
H]thymidine in cell DNA was mea-
sured as described (18).
 
In Vitro Kinase Assays.
 
After stimulation with anti-IgM or
anti-RP-105, the B cells were lysed and Erk2, JNK1/2 or p38
MAP kinase isoforms were immunoprecipitated from B cell ly-
sates by corresponding polyclonal antibodies (16). Assessment of
MAP kinase isoform activity was carried out as described (21).
The phosphorylation of substrates was quantified by Phosphor-
Imager analysis. After analysis the membranes were reprobed with
antibodies to each respective kinase to confirm equivalent immu-
noprecipitation in each sample. Lyn immunoprecipitation, im-
munoblot analysis and determination of Lyn protein kinase activ-
ity were carried out as described (22). Immunoprecipitates were
washed with kinase buffer (20 mM Tris, pH7.2, 10 mM MgCl
 
2
 
,
10 mM MnCl
 
2
 
, 0.1% NP-40) and resuspended in 50 
 
m
 
l of the
same buffer containing 0.5 
 
m
 
g of acid-denatured rabbit muscle
enolase (Sigma Chemical Co., St. Louis, MO) and 10 
 
m
 
Ci of
 
g
 
-[
 
32
 
P]ATP. The phosphorylation reaction was performed at
room temperature and stopped by addition of Laemmli buffer.
Aliquots of the reaction mix were separated on 10% PAGE,
transferred to nitrocellulose membrane and Lyn-mediated enolase
phosphorylation was quantitated by PhosphorImager analysis.
 
Flow Cytometry and Calcium Mobilization.
 
FACS
 
Ò
 
 analysis was
performed on a FACScan
 
Ò
 
 (Becton Dickinson & Co.) and the
data were analyzed using CellQuest v3.1 software (Beckton
Dickinson & Co.). The analysis of Ca
 
2
 
1
 
 mobilization was carried
out as described (21). In some experiments, Fc
 
g
 
 receptors (Fc
 
g
 
R)
on B cells were blocked by preincubation of splenocytes with the
anti–Fc
 
g
 
RII-III mAb 2.4G2. The stained cells were washed and
resuspended in media/Hepes. After establishing base line fluores-
cence in the FITC (530 nm) channel, cells were stimulated by ad-
dition of anti-IgM or anti-RP-105 and data were collected con-
tinuously over a 14-min interval. Results were plotted as the
mean Fluo-3 fluorescence at 20-s intervals.
 
Results
 
Early Signaling Events Induced by Anti–RP-105 Antibodies.
 
Incubation of purified splenic B cells with anti-RP-105 an-
tibody leads to the activation of B cells as determined by
the upregulation of surface MHC class II (Fig. 1, 
 
top
 
), the
costimulatory molecule B7.2 (Fig. 1, 
 
middle
 
) and a strong
dose-dependent proliferative response (Fig. 1, 
 
bottom
 
). The
possible mechanisms of RP-105–mediated B cell activation
were addressed by analyzing RP-105–mediated protein ty-
rosine phosphorylation and Ca
 
2
 
1
 
 
 
mobilization. Both of
these events are known to precede ligand-induced upregu-
lation of costimulatory molecules and proliferation of B
cells (23, 24).
In contrast to the strong induction of protein tyrosine
phosphorylation in anti-IgM-stimulated cells, the treatment
of B cells with anti-RP-105 at the concentration optimal
for B cell proliferation (5 
 
m
 
g/ml) results in a very modest
increase in tyrosine phosphorylation of proteins with mo-
lecular masses ranging from 60 to 95 kD (Fig. 2 
 
a
 
). More-
over, proteins such as Syk, Vav, or Shc, which serve as
common substrates for various receptor-linked protein ty-
rosine kinases (PTKs; reference 23), do not undergo any
major change in degree of phosphorylation upon RP-105
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cross-linking in comparison to the changes seen after treat-
ment with anti-IgM (Fig. 2 
 
b
 
 and data not shown).
Activation of B cells by various agonists such as anti-IgM,
CD40 ligand, or anti-CD38 is accompanied by Ca
 
2
 
1
 
 mobili-
zation from intracellular stores (25–27). In sharp contrast to
the rapid rise in cytosolic Ca
 
2
 
1
 
 concentration induced by
anti-IgM, the incubation of B cells with anti–RP-105 causes
a very slow and gradual increase in cytosolic Ca
 
2
 
1
 
 concen-
tration (Fig. 3 
 
a
 
). Although blockade of Fc
 
g
 
R dramatically
increases the duration of anti-IgM–induced Ca
 
2
 
1
 
 mobiliza-
tion, this treatment has essentially no effect on anti-RP-105–
induced Ca
 
2
 
1
 
 mobilization (Fig. 3 
 
a
 
). These data indicate
that the Fc
 
g
 
R does not regulate anti-RP-105–induced Ca
 
2
 
1
 
mobilization. The role of Ca
 
2
 
1
 
 in RP-105–mediated B cell
activation was further addressed by analyzing the effect of
cyclosporin A (CsA) on anti-RP-105–induced proliferation.
This drug inhibits the Ca
 
2
 
1
 
-dependent phosphatase cal-
cineurin which controls the phosphorylation and, therefore,
nuclear translocation of transcription factor NF-AT in lym-
phocytes (28, 29). Despite the striking differences in kinetics
and amplitude of Ca21 mobilization induced by anti-RP-
Figure 1. RP-105–mediated activation of splenic B cells in vitro.
Splenic B cells were purified and stimulated as described in Materials and
Methods. Histograms show the surface expression levels of MHC class II
(top) or costimulatory molecule CD86 (middle) on B cells incubated for 24 h
in the absence (thin line) or presence of anti-RP-105 antibody (5 mg/ml)
(bold line). For the analysis of anti-RP-105–mediated proliferation, puri-
fied splenic B cells were cultured either at 2 3 105/well (circles) or at 4 3
105/well (squares) with the indicated amounts of anti-RP-105 for 36 h.
[3H]thymidine (1 mCi/well) was added 8 h before cell harvesting. The
proliferation of B cells was determined by the analysis of the amount of
[3H]thymidine incorporated into the DNA of stimulated cells.
Figure 2. Induction of protein tyrosine phosphorylation by anti-RP-
105. Purified wild-type splenic B cells were stimulated with goat anti-
IgM (10 mg/ml) or anti-RP-105 (5 mg/ml) for the indicated periods of
time and cell lysates were prepared. (a) Whole cell lysates (15 mg of pro-
tein) were resolved on 10% SDS-PAGE, transferred to nitrocellulose
membranes and phosphorylation of the transferred proteins was deter-
mined by incubation of membranes with anti-phosphotyrosine antibody
4G10. The two predominant bands seen in all samples at molecular masses
z55 kD represent p53/p56lyn. Equal protein loading was verified by re-
probing the blots with the anti-Syk antibody. (b and c) Whole cell lysates
were immunoprecipitated with anti-Syk antibody, the immunoprecipi-
tates were resolved on 10% PAGE and the amount (b) and phosphoryla-
tion (c) of the immunoprecipitated Syk was analyzed by immunoblotting
with 4G10 mAb. Two protein bands on c reflect a difference in the phos-
phorylation of Syk.
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105 and anti-IgM, the anti-RP-105–induced proliferation of
B cells is inhibited by CsA with the same efficiency as the
proliferation of B cells induced by anti-IgM in combination
with IL-4 (Fig. 3 c). These data suggest that Ca21-dependent
calcineurin activation plays an essential role in the induction
of B cell proliferation by anti-RP-105.
Engagement of various surface-expressed B cell receptors
such as the antigen receptor, the CD19/CD21 complex,
CD22, or CD40 leads to the activation of MAP kinases
ERK2, SAPK/JNK, and p38 (1, 30). Treatment of B cells
with anti-RP-105 results in a dose-dependent activation of
these MAP kinase isoforms (Fig. 4, a–c, lanes 1, 3–5). Acti-
vation of Erk2 and p38 reaches a maximum within 15 min
of RP-105 treatment and diminishes at 45 min, whereas
JNK1/2 shows sustained activation (Fig. 5, a–c, left). Aver-
aged over multiple experiments, activation of MAPK iso-
forms was much stronger after anti-RP-105 treatment than
after anti-IgM stimulation (Table 1). However, the kinetics
of activation of MAPK isoforms by anti-RP-105 is slower
as compared with the previously reported anti-IgM–
induced MAPK activation (16). Although anti-IgM treat-
ment of B cells leads to maximal induction of Erk2 activity
within 3–5 min, the maximal Erk2 activation by anti-RP-
105 requires z15 min (Fig. 5, a–c, left).
The Essential Roles of Lyn, PKCbI/II, and MAP Kinase
Kinase in Anti-RP-105–induced B Cell Proliferation. The low
level of anti-RP-105–induced protein tyrosine phosphory-
lation does not exclude the involvement of PTKs in RP-
105–mediated signaling. Indeed, the dramatic reduction of
anti-RP-105–induced proliferation of xid B cells demon-
strates the essential role of protein tyrosine kinase Btk in
RP-105–mediated signaling (12). The activation of Btk is
partially regulated by Src-family PTKs (31, 32). In B cells
the Src-family kinases are represented mostly by Blk, Fyn
and Lyn (33–35). The role of Src-family PTKs in RP-105–
mediated signaling was addressed by analyzing anti-RP-
105–induced activation of B cells deficient for Blk, Fyn, or
Lyn. RP-105–induced proliferation is unaltered in Blk-
and Fyn-deficient B cells (Fig. 6). In sharp contrast to Blk-
and Fyn-deficient B cells, the proliferative responses of
Lyn-deficient B cells are dramatically reduced as compared
Figure 3. Ca21 mobilization is essential for anti-RP-105–induced B cell proliferation. (a) Purified splenic B cells were stimulated with rabbit anti-IgM
(10 mg/ml) or anti-RP-105 (5 mg/ml) (either with or without prior blocking of FcgR with anti-FcgRII-III-mAb). Mobilization of intracellular Ca21
was analyzed by flow cytometry as described in Materials and Methods. Antibodies were added at the time points indicated by the arrow. Closed symbols
represent cells stimulated with rabbit anti-IgM (diamonds and triangles, with or without prior blocking of FcgR, respectively); open symbols represent
stimulation with anti-RP-105 (circles and squares, with or without prior blocking of FcgR, respectively). (b) Splenic B cells were stimulated with anti-IgM
(10 mg/ml), anti-RP-105 (5 mg/ml) or anti-IgM in combination with anti-RP-105 (at the concentrations mentioned above) and calcium mobilization
was analyzed. Closed triangles represent stimulation with anti-IgM alone, open circles represent stimulation with anti-RP-105 alone, and open squares
with crosses represent stimulation with both anti-IgM and anti-RP-105. (c) Inhibition of the RP-105–induced B cell proliferation by cyclosporin A
(CsA). B cells (5 3 105/well) were stimulated with anti-IgM (2.5 mg/ml) and IL-4 (25 U/ml; squares) or with anti-RP-105 (5 mg/ml) (circles) in the pres-
ence or absence of the indicated concentrations of CsA for 36 h. Cyclosporin A (Sigma Chemical Co.) was dissolved at 2.5 mg/ml in ethanol and then
further diluted in culture medium. Each symbol shows the degree of inhibition (%) of [3H]thymidine incorporation into the DNA of stimulated purified
splenic B cells in the presence of CsA. Representative result from one of three independent experiments is shown. The triplicate values for proliferation
were as follows: unstimulated B cells 2,978 6 126; B cells stimulated with: anti-IgM plus IL-4 5,625 6 583; anti-RP-105 26,537 6 2,203 cpm.
Figure 4. The dose-dependent activation of MAP kinase isoform by
RP-105 and anti-IgM–mediated negative regulation of RP-105–medi-
ated MAPK activation. Purified splenic B cells from wild-type C57BL/6
and lyn2/2 mutant mice (4 3 106 cells/ml of media) were stimulated for
15 min with anti-IgM, anti-RP-105 at the indicated concentrations or
with the combination of both. The cell lysates (50 mg of protein) were
immunoprecipitated with anti-Erk2 (a), anti-JNK1/2 (b), or anti-p38 (c),
and the immunoprecipitates were used for in vitro kinase assays (see Ma-
terials and Methods). Phosphorylated substrates were resolved on a 10%
PAGE and quantitated by PhosphorImager analysis. The n-fold activation
was determined relative to the levels of MAP kinase activity in unstimu-
lated cells.
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with responses of the wild-type (Fig. 6). The surface expres-
sion levels of RP-105 in Lyn-deficient B cells are similar to
those in wild-type B cells (data not shown), excluding that
reduction of RP-105 signaling is due to the downregulation
of RP-105 expression in the absence of Lyn.
In view of the essential role of Lyn in RP-105–mediated
B cell proliferation, the activation of Lyn by anti-RP-105
was analyzed by a sensitive immunocomplex kinase assay
(22). Incubation of wild-type B cells with anti-RP-105 or
anti-IgM results in increase of protein tyrosine kinase activity
of Lyn as determined by phosphorylation of the exogenous
substrate enolase and increase of Lyn autophosphorylation
(Fig. 7 a). The kinase activity of Lyn in anti-IgM–treated B
cells reaches the maximum after 1 min and declines to the
basal level of activity after 15 min of incubation (Fig. 7 a). In
contrast, the activation of Lyn by RP-105, although not as
high as in anti-IgM–treated cells, remains constant for 30
min at least (Fig. 7). Notably, the amounts of immunoreac-
tive Lyn did not vary between the samples (Fig. 7 b).
The defect of anti-RP-105–induced activation of Lyn-
deficient B cells and the previously described impairment
of anti-RP-105–induced proliferation of xid B cells (12)
suggest a functional link between Lyn and Btk within the
RP-105–dependent signaling cascade. In B lymphocytes
and mast cells Btk appears to be associated with protein ki-
nase C b I/II (PKCbI/II) (36). The physiological impor-
tance of Btk-PKCbI/II interaction in B cell function is
underscored by the demonstration of essentially identical
profiles of B cell signaling defects in PKCbI/II-deficient
and xid B cells (18). To determine whether PKCbI/II plays
a role in RP-105–mediated B cell activation, the anti-RP-
105–induced proliferation of PKCbI/II-deficient B cells
was analyzed. The PKCbI/II-deficient B cells express RP-
105 at levels similar to those in control B lymphocytes (data
not shown). Similar to xid B cells, which do not proliferate
in response to anti-RP-105 (12), treatment of PKCbI/II-
deficient B cells with anti-RP-105 does not induce detect-
able proliferative responses (Fig. 6).
Activation of MAP kinase isoforms by anti-RP-105 and
impaired RP-105–mediated activation of Lyn-deficient,
xid, or PKCbI/II-deficient B cells suggests a link between
the Lyn-Btk/PKCbI/II signaling chain and MAP kinases
in the RP-105–dependent signaling cascade. Indeed, the
treatment of Lyn-deficient B cells with anti-RP-105 is ac-
companied by a significantly weaker activation of MAP ki-
nase isoforms as compared with wild-type B cells (Fig. 5
and Table 1). A similar result was obtained by the analysis
Figure 5. The kinetics of RP-
105–mediated activation of MAPK
isoforms in wild-type and lyn2/2
B cells. Purified splenic B cells
from wild type C57BL/6 and
lyn2/2 mice (4 3 106 cells/ml of
media) were stimulated with anti-
IgM (10 mg/ml) or anti-RP-105
(5 mg/ml) for the indicated periods
of time and cell lysates were pre-
pared. Immunoprecipitations and
determination of Erk2 (a), JNK1/2
(b), and p38 (c) kinase activities
were carried out as described for
Fig. 4.
Figure 6. Proliferative responses of blk2/2, fyn2/2, lyn2/2, PKCbI/
II2/2, and dnMEK B cells to anti-RP-105. Splenic B cells isolated from
wild-type control mice (open symbols) or mutant mice (filled symbols) were
cultured in the absence (triangles) or presence (circles) of anti-RP-105 (5
mg/ml). Each symbol represents the mean value of triplicate measure-
ments in individual experiments. For the analysis of blk2/2, PKCbI/II2/2,
and dnMEK, 129/Sv mice-derived B cells were used as a control. The
C57BL/6 mice-derived B cells were used as a control for the analysis of
responses of lyn2/2 B lymphocytes.
Figure 7. Anti-RP-105–induced activation of Lyn kinase. Purified
splenic B cells from wild-type C57BL/6 mice were treated with either
goat anti-IgM (10 mg/ml) or anti-RP-105 (5 mg/ml) for the indicated
periods of time. 50 mg of lysate protein were used for anti-Lyn immuno-
precipitation/immune complex kinase assay with enolase added as an ex-
ogenous substrate (see Materials and Methods). (a) The products of the in
vitro kinase reactions were resolved on a 10% PAGE and relative phos-
phorylation of enolase (normalized to unstimulated cells) was quantitated
by PhosphorImager analysis. (b) The amount of Lyn in whole cell lysates
(15 mg) was determined by immunoblot analysis with anti-Lyn antibody.
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of anti-RP-105–induced MAP kinase activation in xid B
cells (data not shown). The role of MAP kinases in anti-
RP-105–induced B cell activation was further addressed by
the analysis of anti-RP-105–induced proliferation of splenic
B cells expressing the dominant-negative form of MAP ki-
nase kinase (MEK; Carsetti, R., and A. Tarakhovsky,
manuscript in preparation). B cells expressing the dominant
negative mutant of MEK (dnMEK) were derived in vivo
from chimeric RAG-2–deficient mice in which the lym-
phoid system was reconstituted by ES cells carrying multi-
ple copies of the dnMEK transgene under the control of B
cell–specific regulatory elements (Carsetti, R., and A. Tara-
khovsky, manuscript in preparation). Expression of dnMEK
in B cells suppresses the activation of MAP kinase by stim-
uli such as anti-IgM or phorbol ester in combination with
ionomycin (Carsetti, R., and A. Tarakhovsky, manuscript
in preparation). Incubation of dnMEK-expressing B cells
with anti-RP-105 antibody at a concentration inducing
strong proliferation of wild-type control B cells does not in-
duce the proliferation of transgenic B cells (Fig. 6).
Counterregulation by sIgM of RP-105–mediated MAP Kinase
Activation and Calcium Mobilization. In spite of the strong
proliferation-inducing potential of anti-RP-105, the simul-
taneous antibody-mediated ligation of sIgM and RP-105 in
vitro leads to B cell growth arrest and death (15). The de-
gree of MAP kinase activation and/or changes in the pat-
tern of activated MAPK isoforms induced by engagement
of various receptor molecules define the fate of responding
cells (37). To determine whether the negative regulation of
RP-105 signaling by sIgM could be detected at the level of
MAP kinase isoform activation, purified splenic B cells
were incubated with variable amounts of anti-RP-105 in
the presence or absence of anti-IgM. Antibody-mediated
cross-linking of RP-105 results in a dose-dependent in-
crease of the activities of Erk2, JNK1/2, and p38 (Fig. 4).
The level of MAP kinase isoform activation by anti-RP-
105 at a concentration optimal for B cell proliferation (5
mg/ml) is significantly higher than that induced by anti-
IgM. However, simultaneous incubation of B cells with
anti-RP-105 and anti-IgM reduces the amplitude of MAP
kinase isoform activation to levels characteristic for anti-
IgM–induced MAP kinase activation alone (Fig. 4). The
dominance of antigen receptor-mediated signaling is simi-
larly observed in lyn2/2 B cells, where low levels of anti-
RP-105–induced MAPK activation become significantly
higher upon costimulation with anti-IgM (Fig. 4).
The negative regulation of RP-105 signals by signals
through the antigen receptor were also seen at the level of
Ca21 mobilization. Coincubation of B cells with anti-IgM
and RP-105 induced a Ca21 mobilization response that is
indistinguishable from Ca21 mobilization in cells treated
with anti-IgM alone (Fig. 3 b).
Discussion
This study advances the understanding of two questions
regarding the activation of B cells by RP-105. First, can a
biochemical pathway of RP-105–mediated intracellular
signaling be identified? Second, what is the mechanism of
negative regulation of RP-105–mediated B cell activation
by the antigen receptor? Using genetic and biochemical ap-
proaches we revealed a critical role of Lyn in RP-105–
mediated B cell activation. Lyn is one of the most abundant
Src-family PTKs in B cells and is known to be associated
with the antigen receptor and the CD19 coreceptor (38,
39). Although an association of Lyn with RP-105 has not
been detected (Miyake, K., unpublished observation), the
rapid though modest increase of kinase activity of Lyn
upon anti-RP-105 treatment suggests a proximal location
of Lyn with regard to the putative RP-105 signaling com-
plex. The activation of Lyn kinase by RP-105 does not re-
sult in a significant increase of the tyrosine phosphorylation
of various other cellular proteins in the activated cells. This
result is not completely unexpected in view of the minimal
changes in tyrosine phosphorylation of various proteins in
anti-IgM–stimulated Lyn-deficient B cells as compared
with wild-type B cells (16). Hence, both in B cell antigen
receptor- and RP-105–dependent signaling pathways Lyn
might be responsible for the phosphorylation of substrates
the expression and/or degree of phosphorylation of which
do not allow their detection by anti-phosphotyrosine im-
munoblot analysis of crude cell lysates.
The defective RP-105–mediated activation of Lyn-defi-
cient and xid B cells suggests a possible link between Lyn
and Btk in the RP-105 signaling cascade. Among the Src-
family PTKs expressed in B cells, Lyn seems to play a lead-
ing role in antigen receptor-mediated phosphorylation and
activation of Btk (31). The lack of effect of Blk and Fyn on
RP-105–induced B cell activation suggests that among the
three major Src-family PTKs in B cells Lyn is likely to be
responsible for Btk activation by RP-105.
As with Lyn-deficient and xid B cells, PKCbI/II-defi-
Table 1. Activation of MAPK Isoforms in Wild-type and lyn2/2 
B Cells
Genotype Stimulus
n-Fold activation compared 
to unstimulated cells
MAPK isoform
Erk2 JNK1/2 p38
C57BL/6 anti-RP-105 21 6 6 10 6 2 6 6 1
anti-IgM 6 6 2 3 6 0.8 3 6 1
Lyn2/2 anti-RP-105 6 6 1 3 6 0.8 2 6 0.2
anti-IgM 23 6 9 14 6 3 4 6 1
Enzymatic activation of MAPK isoforms was determined after 15 min
of B cell stimulation as described in the legend to Fig. 5. Enzymatic ac-
tivity in resting wild-type cells was given an arbitrary value of 1. In each
experiment splenic B cells isolated from at least four mice were used.
The n-fold induction of kinase activity (mean 6 standard error) from
three to five separate experiments are presented.
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cient cells cannot be successfully activated by anti-RP-105.
The ability of Btk to bind PKCbI/II and the virtual iden-
tity of immunodeficiency syndromes in xid and PKCbI/II-
deficient mice (18) strongly support the existence of a Btk/
PKCbI/II signaling module and its importance for B cell ac-
tivation. In B cells, PKCbI/II together with PKCa repre-
sent the subfamily of PKCs the activation of which is depen-
dent on Ca21 and diacylglycerol (40). Importantly, PKCbI/II
appears to be activated by significantly lower concentrations
of Ca21 than PKCa (41, 42). Therefore, it seems likely that
the very slow and gradual Ca21 mobilization induced by
anti-RP-105 would be sufficient to induce the activation of
PKCbI/II, but not to induce the activation of PKCa. This
hypothesis is currently under investigation.
Several lines of evidence support the importance of MAP
kinase in RP-105–mediated activation of B cells. First, the
activation of B cells by RP-105 leads to activation of MAP
kinase isoforms Erk2, p38, and Jun kinase (JNK1/2). Sec-
ond, anti-RP-105 fails to induce proliferation of B cells ex-
pressing the dominant negative form of Erk-specific (43,
44) MAPK kinase (MEK). The impaired RP-105–medi-
ated activation of all three MAP kinase isoforms in the ab-
sence of Lyn and our preliminary data on the lack of MAP
kinase activation in xid B cells support a possible connec-
tion between the RP-105 and MAP kinase signaling cas-
cades via the Lyn-Btk/PKCbI/II module.
The similarity between toll and RP-105 as well as the
ability of anti-RP-105 antibody to induce polyclonal acti-
vation of B cells in vitro supports a possible involvement of
RP-105 in the regulation of innate immune responses. The
activation of lymphocytes during innate immune response
plays an important role in the efficient recruitment of acti-
vated B cells into antigen-driven adaptive responses (3).
However, it seems conceivable that the switch from innate
to adaptive immune responses may require the existence of
mechanisms promoting antigen-specific responses at the
expense of polyclonal B cell activation. In this study we
have tried to address the mechanism of negative regulation
of RP-105–mediated B cell activation by antigen receptor-
derived signal(s). Involvement of Lyn, Btk, PKCbI/II, and
MAP kinases in both sIgM- and RP-105–mediated activa-
tion implies the existence of a signaling pathway(s) com-
mon for both of the receptors. In contrast to Btk and
PKCbI/II, which both play positive roles in anti-RP-105–
and IgM-mediated B cell activation, Lyn appears to have
different functions in sIgM- and RP-105–mediated signal-
ing. Although the sIgM-mediated MAP kinase activation is
negatively controlled by Lyn (16), the presence of Lyn is
essential for RP-105–induced MAP kinase activation. The
relatively stronger activation of Lyn kinase by anti-IgM
than by anti-RP-105 may reflect more efficient recruit-
ment of Lyn to the B cell antigen receptor (BCR) complex
as compared with the putative RP-105 signaling complex.
In such a case the simultaneous ligation of BCR and RP-
105 will reduce the amount of Lyn that could be used by
RP-105 signaling complex and block the RP-105–induced
MAP kinase activation. This, in turn, may lead to the onset
of the antigen receptor-specific pattern of MAP kinase acti-
vation and reprogramming of B cell responses. Assuming
that RP-105 activation in vivo is regulated by specific
ligand(s), the antagonistic relation between antigen receptor-
and RP-105–mediated signaling predicts a temporal and/or
spatial separation of putative RP-105 ligand- and antigen–
induced B cell activation during immune responses.
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